The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Timing of Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus (HIV)-Associated Tuberculous Meningitis
Open accessAbstract
BACKGROUND: The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of immediate versus deferred ART in patients with HIV-associated tuberculous meningitis to determine whether immediate ART reduced the risk of death. Antiretroviral drugs (zidovudine, lamivudine, and efavirenz) were started either at study entry or 2 months after randomization. All patients were treated with standard antituberculosis treatment, adjunctive dexamethasone, and prophylactic co-trimoxazole and were followed up for 12 months. We conducted intention-to-treat, per-protocol, and prespecified subgroup analyses. RESULTS: A total of 253 patients were randomized, 127 in the immediate ART group and 126 in the deferred ART group; 76 and 70 patients died within 9 months in the immediate and deferred ART groups, respectively. Immediate ART was not significantly associated with 9-month mortality (hazard ratio [HR], 1.12; 95% confidence interval [CI], .81-1.55; P = .50) or the time to new AIDS events or death (HR, 1.16; 95% CI, .87-1.55; P = .31). The percentage of patients with severe (grade 3 or 4) adverse events was high in both arms (90% in the immediate ART group and 89% in the deferred ART group; P = .84), but there were significantly more grade 4 adverse events in the immediate ART arm (102 in the immediate ART group vs 87 in the deferred ART group; P = .04). CONCLUSIONS: Immediate ART initiation does not improve outcome in patients presenting with HIV-associated tuberculous meningitis. There were significantly more grade 4 adverse events in the immediate ART arm, supporting delayed initiation of ART in HIV-associated tuberculous meningitis. Clinical Trials Registration. ISRCTN63659091.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H. (2009) · PsycEXTRA Dataset · doi:10.1037/e537722009-001 · Cited by 1,343
Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults
Thwaites, G. E., Bang, N. D., Dung, N. H., Quy, H. T., Oanh, D. T. T., Thoa, N. T. C., Hien, N. Q., Thuc, N. T., Hai, N. N., Lan, N. T. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040573 · Cited by 1,043
Self-citationDexamethasone for treatment of tuberculous meningitis in adolescents and adults
Tunkel, A. R. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0059-0 · Cited by 671
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T., Nair, G., Bamber, S., Singh, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905848 · Cited by 666
Tuberculous Meningitis in Patients Infected with the Human Immunodeficiency Virus
Berenguer, J., Moreno, S., Laguna, F., Vicente, T., Adrados, M., Ortega, A., González-LaHoz, J., & Bouza, E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261004 · Cited by 432
Wiktor, S. Z., Sassan-Morokro, M., Grant, A. D., Abouya, L., Karon, J. M., Maurice, C., Djomand, G., Ackah, A., Domoua, K., Kadio, A., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03465-0 · Cited by 418
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
Dean, G. L., Edwards, S. G., Ives, N. J., Matthews, G., Fox, E. F., Navaratne, L., Fisher, M., Taylor, G. P., Miller, R., Taylor, C. B., et al. (2002) · AIDS · doi:10.1097/00002030-200201040-00010 · Cited by 354
Manosuthi, W., Chottanapand, S., Thongyen, S., Chaovavanich, A., & Sungkanuparph, S. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000230521.86964.86 · Cited by 258
Makadzange, A. T., Ndhlovu, C. E., Takarinda, K., Reid, M., Kurangwa, M., Gona, P., & Hakim, J. G. (2010) · Clinical Infectious Diseases · doi:10.1086/652652 · Cited by 221
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Perez-Velez, C. M., & Marais, B. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1008049 · Cited by 572
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013607 · Cited by 532
on behalf of the Tuberculous Meningitis International Research Consortium, Wilkinson, R. J., Rohlwink, U., Misra, U. K., van Crevel, R., Mai, N. T. H., Dooley, K. E., Caws, M., Figaji, A., Savic, R., et al. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.120 · Cited by 508
Self-citationTiming of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Tuberculous meningitis: more questions, still too few answers
Thwaites, G. E., van Toorn, R., & Schoeman, J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70168-6 · Cited by 482
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., Borm, G., Aarnoutse, R. E., & van Crevel, R. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70264-5 · Cited by 344
Scaling up interventions to achieve global tuberculosis control: progress and new developments
Raviglione, M., Marais, B., Floyd, K., Lönnroth, K., Getahun, H., Migliori, G. B., Harries, A. D., Nunn, P., Lienhardt, C., Graham, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60727-2 · Cited by 340
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Beardsley, J., Wolbers, M., Kibengo, F. M., Ggayi, A.-B. M., Kamali, A., Cuc, N. T. K., Binh, T. Q., Chau, N. V. V., Farrar, J., Merson, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509024 · Cited by 315
Self-citationIntensified Antituberculosis Therapy in Adults with Tuberculous Meningitis
Heemskerk, A. D., Bang, N. D., Mai, N. T. H., Chau, T. T. H., Phu, N. H., Loc, P. P., Chau, N. V. V., Hien, T. T., Dung, N. H., Lan, N. T. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507062 · Cited by 310
Self-citationImmune reconstitution inflammatory syndrome: the trouble with immunity when you had none
Barber, D. L., Andrade, B. B., Sereti, I., & Sher, A. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2712 · Cited by 169
Clinical Aspects of Adult Tuberculosis
Loddenkemper, R., Lipman, M., & Zumla, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017848 · Cited by 140
Metadata
- Authors
- Torok, M. E., Yen, N. T. B., Chau, T. T. H., Mai, N. T. H., Phu, N. H., Mai, P. P., Dung, N. T., Chau, N. V. V., Bang, N. D., Tien, N. A., Minh, N. H., Hien, N. Q., Thai, P. V. K., Dong, D. T., Anh, D. T. T., Thoa, N. T. C., Hai, N. N., Lan, N. N., Lan, N. T. N., Quy, H. T., Dung, N. H., Hien, T. T., Chinh, N. T., Simmons, C. P., de Jong, M., Wolbers, M., & Farrar, J. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-18
- Volume
- 52
- Issue
- 11
- Pages
- 1374-1383
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2163117709
- Cited by
- 312
- References
- 21
- FWCI
- 31.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.